Should I Change Anticoagulane in Veno-Venous ECMO?

Area of Science:

• Critical Care Medicine
• Cardiovascular Science
• Pharmacology

Background:

• Extracorporeal membrane oxygenation (ECMO) anticoagulation lacks standardized, high-quality data, leading to practice variations.
• Unfractionated heparin (UFH) is commonly used, but alternative anticoagulants are being explored.
• Bivalirudin offers a direct thrombin inhibition mechanism.

Purpose of the Study:

• To investigate the safety, efficacy, and cost-effectiveness of bivalirudin versus UFH in ECMO patients.
• To compare anticoagulation control using activated partial thromboplastin time (aPTT) between the two agents.
• To assess resource utilization and costs associated with each anticoagulant.

Main Methods:

• Retrospective evaluation of 56 patients undergoing Veno-Venous ECMO for acute respiratory distress syndrome.
• Comparison between 25 patients on UFH and 31 patients on bivalirudin.
• Analysis of time to target aPTT, percentage of time in therapeutic range, transfusion requirements, and costs.

Main Results:

• No significant difference in time to target aPTT or percentage of time within the therapeutic aPTT range between bivalirudin and UFH groups.
• Lower median erythrocyte suspension and fresh frozen plasma replacement in the bivalirudin group compared to the UFH group.
• Significantly higher costs associated with bivalirudin compared to UFH.

Conclusions:

• Bivalirudin demonstrates comparable anticoagulation efficacy to UFH in ECMO patients.
• Bivalirudin use may reduce the need for blood product transfusions.
• The cost of bivalirudin is substantially higher than UFH.